Evaluation of PastoCovac Plus Vaccine As a Booster Dose on Vaccinated Individuals with Inactivated COVID-19 Vaccine

Overview

Journal Heliyon

Specialty Social Sciences

Date 2023 Oct 9

PMID 37810803

Authors

Behrokh Farahmand

Mona Sadat Larijani

Fatemeh Fotouhi

Alireza Biglari

Rahim Sorouri

Fahimeh Bagheri Amiri

Ali Eslamifar

Tahmineh Jalali

Mostafa Salehi-Vaziri

Mohammad Banifazl

Sarah Dahmardeh

Azita Eshratkhah Mohammadnejad

Anahita Bavand

Mahsa Tavakoli

Vicente Verez-Bencomo

Ehsan Mostafavi

Hassan Noori Daloii

Fatemeh Ashrafian

Masoumeh Saberpour

Amitis Ramezani

Affiliations

Soon will be listed here.

Abstract

COVID-19 pandemic has been managed through global vaccination programs. However, the antibody waning in various types of vaccines came to notice. Hereby, PastoCovac Plus as a protein subunit vaccine was investigated in immunized health care workers by COVAXIN (BBV152). The booster vaccine was recommended at least three months post the second dose of COVAXIN. Sera collection was done before and after each injection. SARS-CoV-2 PCR test was done monthly to detect any asymptomatic and symptomatic vaccine breakthrough. 47.9 and 24.3% of the participants were seronegative for anti-N and anti-S antibodies three months after the second dose of COVAXIN, respectively. On average, fold-rises of 70, 93, 8 and mean-rises of 23.32, 892.4, 5.59 were recorded regarding neutralizing antibody, quantitative and semi-quantitative anti-Spike antibody, respectively. Anti-Spike and neutralizing antibodies seroconversion was seen 59.3% and 45.7%, respectively. The vaccine breakthrough assessment showed that all the isolated samples belonged to SARS-CoV-2 Delta variant. PastoCovac Plus boosting is strongly recommended in combination with inactivated vaccine platforms against SARS-CoV-2.

Citing Articles

Assessment of COVID-19 Vaccine Impact on Women's Menstrual Health within an 18-Month Follow-Up.

Sadat Larijani M, Eybpoosh S, Doroud D, Bavand A, Moradi L, Ashrafian F Obstet Gynecol Int. 2024; 2024:7344506.

PMID: 39364209 PMC: 11449560. DOI: 10.1155/2024/7344506.

Improving Vaccine Response through Probiotics and Micronutrient Supplementation: Evaluating the Role of TLR5 in Adult Female BALB/c Mice.

Eftekhari Z, Doroud D, Tajabadi-Ebrahimi M, Kazemi-Lomedasht F Curr Pharm Des. 2024; 31(3):233-242.

PMID: 39257145 DOI: 10.2174/0113816128310203240823053538.

Potential Protectivity of a Conjugated COVID-19 Vaccine against Tetanus.

Doroud D, Ashrafian F, Javadi A, Dahmardeh S, Banifazl M, Bavand A Vaccines (Basel). 2024; 12(3).

PMID: 38543877 PMC: 10974556. DOI: 10.3390/vaccines12030243.

Long-term rheumatoid manifestations as a consequence of COVID-19 and/or vaccination: A case report after a 2-year follow-up.

Sadat Larijani M, Banifazl M, Karami A, Ramezani A Heliyon. 2024; 10(3):e24982.

PMID: 38317942 PMC: 10840001. DOI: 10.1016/j.heliyon.2024.e24982.

Lessons from COVID-19 Pandemic: A Successful Policy and Practice by Pasteur Institute of Iran.

Sadat Larijani M, Biglari A, Sorouri R, Salehi-Vaziri M, Doroud D, Azadmanesh K Iran Biomed J. 2024; 28(1):1-7.

PMID: 38224028 PMC: 10994636. DOI: 10.61186/ibj.3964.

References

Shrotri M, Navaratnam A, Nguyen V, Byrne T, Geismar C, Fragaszy E . Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet. 2021; 398(10298):385-387. PMC: 8285117. DOI: 10.1016/S0140-6736(21)01642-1. View

Salehi-Vaziri M, Jalali T, Farahmand B, Fotouhi F, Banifazl M, Pouriayevali M . Clinical characteristics of SARS-CoV-2 by re-infection vs. reactivation: a case series from Iran. Eur J Clin Microbiol Infect Dis. 2021; 40(8):1713-1719. PMC: 7972329. DOI: 10.1007/s10096-021-04221-6. View

Sadat Larijani M, Pouriayevali M, Sadat S, Ramezani A . Production of Recombinant HIV-1 p24-Nef Protein in Two Forms as Potential Candidate Vaccines in Three Vehicles. Curr Drug Deliv. 2020; 17(5):387-395. DOI: 10.2174/1567201817666200317121728. View

Ramezani A, Sorouri R, Maghsoudi S, Dahmardeh S, Doroud D, Sadat Larijani M . PastoCovac and PastoCovac Plus as protein subunit COVID-19 vaccines led to great humoral immune responses in BBIP-CorV immunized individuals. Sci Rep. 2023; 13(1):8065. PMC: 10195798. DOI: 10.1038/s41598-023-35147-y. View

Ai J, Zhang H, Zhang Q, Zhang Y, Lin K, Fu Z . Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern. Cell Res. 2021; 32(1):103-106. PMC: 8609258. DOI: 10.1038/s41422-021-00590-x. View

Sofian M, Khansarinejad B, Ghaznavi-Rad E, Shokoohi F, Mazaherpour H, Farmani F . SARS-CoV-2 Viral Shedding and Associated Factors among COVID-19 Inpatients and Outpatients. Interdiscip Perspect Infect Dis. 2022; 2022:1411106. PMC: 9207016. DOI: 10.1155/2022/1411106. View

Choi A, Koch M, Wu K, Chu L, Ma L, Hill A . Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med. 2021; 27(11):2025-2031. PMC: 8604720. DOI: 10.1038/s41591-021-01527-y. View

Sofian M, Velayati A, Banifazl M, Fotouhi F, Sadat Larijani M, Afzali N . SARS-CoV‑2, a virus with many faces: a series of cases with prolonged persistence of COVID-19 symptoms. Wien Med Wochenschr. 2020; 171(1-2):3-6. PMC: 7734614. DOI: 10.1007/s10354-020-00793-8. View

Sadat S, Aghadadeghi M, Yousefi M, Khodaei A, Sadat Larijani M, Bahramali G . Bioinformatics Analysis of SARS-CoV-2 to Approach an Effective Vaccine Candidate Against COVID-19. Mol Biotechnol. 2021; 63(5):389-409. PMC: 7902242. DOI: 10.1007/s12033-021-00303-0. View

10.

Duarte-Salles T, Prieto-Alhambra D . Heterologous vaccine regimens against COVID-19. Lancet. 2021; 398(10295):94-95. PMC: 8233006. DOI: 10.1016/S0140-6736(21)01442-2. View

11.

Gorry C . SOBERANA, Cuba's COVID-19 Vaccine Candidates: Dagmar García-Rivera PhD. MEDICC Rev. 2020; 22(4):10-15. DOI: 10.37757/MR2020.V22.N4.11. View

12.

Turakhia Y, Thornlow B, Hinrichs A, De Maio N, Gozashti L, Lanfear R . Ultrafast Sample placement on Existing tRees (UShER) enables real-time phylogenetics for the SARS-CoV-2 pandemic. Nat Genet. 2021; 53(6):809-816. PMC: 9248294. DOI: 10.1038/s41588-021-00862-7. View

13.

Majeed A, Papaluca M, Molokhia M . Assessing the long-term safety and efficacy of COVID-19 vaccines. J R Soc Med. 2021; 114(7):337-340. PMC: 8276333. DOI: 10.1177/01410768211013437. View

14.

Sadat Larijani M, Sorouri R, Eybpoosh S, Doroud D, Moradi L, Ahmadinezhad M . Assessment of long-term adverse events regarding different COVID-19 vaccine regimens within an 18-month follow-up study. Pathog Dis. 2023; 81. DOI: 10.1093/femspd/ftad010. View

15.

Sadat Larijani M, Ashrafian F, Bagheri Amiri F, Banifazl M, Bavand A, Karami A . Characterization of long COVID-19 manifestations and its associated factors: A prospective cohort study from Iran. Microb Pathog. 2022; 169:105618. PMC: 9176176. DOI: 10.1016/j.micpath.2022.105618. View

16.

Yadav P, Ella R, Kumar S, Patil D, Mohandas S, Shete A . Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques. Nat Commun. 2021; 12(1):1386. PMC: 7925524. DOI: 10.1038/s41467-021-21639-w. View

17.

Sette A, Crotty S . Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. PMC: 7803150. DOI: 10.1016/j.cell.2021.01.007. View

18.

Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V . Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021; 398(10317):2173-2184. PMC: 8584828. DOI: 10.1016/S0140-6736(21)02000-6. View

19.

Choudhary H, Parai D, Dash G, Kshatri J, Mishra N, Choudhary P . Persistence of Antibodies Against Spike Glycoprotein of SARS-CoV-2 in Healthcare Workers Post Double Dose of BBV-152 and AZD1222 Vaccines. Front Med (Lausanne). 2022; 8:778129. PMC: 8727751. DOI: 10.3389/fmed.2021.778129. View

20.

Sadat Larijani M, Doroud D, Banifazl M, Karami A, Bavand A, Ashrafian F . A landscape on disorders following different COVID-19 vaccination: a systematic review of Iranian case reports. Eur J Med Res. 2023; 28(1):542. PMC: 10676592. DOI: 10.1186/s40001-023-01531-7. View